TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Hydra TAVR valve gains key approval as global reach continues to grow
The self-expanding device is now available in more than 20 countries and received CE mark approval back in 2020. However, it has not yet been approved by the U.S. Food and Drug Administration for use in the United States.
SAVR outperforms TAVR in patients with bicuspid aortic valves
BAV patients are often excluded from TAVR trials, creating uncertainty about the best way to treat that population when aortic valve replacement is required. To learn more, researchers tracked CMS data from 2018 to 2022, presenting their findings in The Annals of Thoracic Surgery.
Treating AFib patients with TAVR still linked to elevated risks
While the technology and techniques associated with TAVR have advanced over the years, treating patients who present with baseline atrial fibrillation is still associated with certain risks.
Years of progress have made TAVR more effective when treating concomitant mitral stenosis
Newer balloon-expandable TAVR valves are associated with much better outcomes for patients presenting with both severe AS and severe MS than older models.
TAVR/PCI bests SAVR/CABG when treating severe AS and complex CAD
Percutaneous treatment was linked to improved survival and fewer adverse events than surgery when patients presented with both symptomatic severe aortic stenosis and complex coronary artery disease.

ElectroDucer Sleeve PCI TAVR EuroIntervention

New direct wire pacing device shows potential during PCI and TAVR, first-in-human study finds

Early evidence suggests the Electroducer Sleeve is safe and effective among patients presenting for certain interventional procedures.

February 27, 2023

How CAD, PCI affect TAVR outcomes among men and women

According to new research published in the American Journal of Cardiology, complex CAD appears to affect long-term TAVR outcomes much more for women than it does for men.

February 14, 2023

Balloon expansion deployment of an Edwards Lifesciences Sapien 3 transcatheter aortic valve replacement (TAVR) device.

New Jersey hospital performs 4,000th TAVR procedure

Morristown Medical Center first started performing TAVR procedures in 2011 and is now home to one of the largest TAVR programs in the United States.

February 7, 2023

Greater access to TAVR linked to better patient outcomes

How does access to care influence short-term TAVR outcomes? Researchers explored data from nearly 22,000 patients to find out.

February 7, 2023

Comprehensive heart teams are rewriting the rules of patient care

Multidisciplinary heart teams are growing more and more popular among hospitals and health systems all over the world. What started as a way to select TAVR patients has become something much more important.

February 6, 2023

A transcatheter aortic valve replacement (TAVR) procedure being performed at Intermountain Healthcare. Image from Intermountain Healthcare

TAVR and PAD: What cardiologists need to know

TAVR patients presenting with peripheral artery disease face significantly higher in-hospital risks, according to a new study published in Current Problems in Cardiology.

February 6, 2023

Samir Kapadia, MD, chairman of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute at Cleveland Clinic, explains why he believes the results of the late-breaking PROTECTED TAVR testing the use of a TAVR cerebral protection device were positive, although it did not meet its primary endpoint.

VIDEO: Exploring the use of cerebral protection devices during TAVR

Samir Kapadia, MD, chair of the department of cardiovascular medicine at Cleveland Clinic, shared his perspective on the use of cerebral protection devices during TAVR procedures.

February 3, 2023

Why are post-TAVR stroke rates higher at comprehensive stroke centers?

One of the more likely reasons is simple: specialty centers have better tools for identifying signs of stroke.

February 1, 2023

TAVR

Hydra TAVR valve gains key approval as global reach continues to grow

SAVR outperforms TAVR in patients with bicuspid aortic valves

Treating AFib patients with TAVR still linked to elevated risks

Years of progress have made TAVR more effective when treating concomitant mitral stenosis

TAVR/PCI bests SAVR/CABG when treating severe AS and complex CAD